Joseph Lightsey, MD
Clinical Cardiac Electrophysiology · Augusta, GANPI 1033522990
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (38.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $13,875 and has fallen 57.6% since, to $5,886 in 2025.
Across 314 payments — averaging $141.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$32K
- Boston Scientific$5K
- Biosense Webster, Inc.$2K
- Biotronik Inc.$2K
- Philips North America LLC$808
- Abbott$603
- plus $2K from 24 others
What the payments were for
- Grants$17,00038%
- Travel & lodging$16,09536%
- Food & beverage$10,96325%
- Education$5181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 126 | $31,658 |
| Boston Scientific | 26 | $5,364 |
| Biosense Webster, Inc. | 47 | $2,181 |
| Biotronik Inc. | 14 | $1,554 |
| Philips North America LLC | 1 | $808 |
| Abbott | 7 | $603 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $438 |
| Pfizer | 20 | $317 |
| Cardiva Medical, Inc. | 4 | $278 |
| Novartis | 17 | $261 |
| Lantheus Medical Imaging, Inc. | 2 | $131 |
| Johnson & Johnson | 9 | $128 |
| Amgen | 8 | $115 |
| BTG International Inc. | 1 | $101 |
| Abiomed | 1 | $90 |
| Braemar Manufacturing, LLC | 1 | $73 |
| Boehringer Ingelheim | 2 | $70 |
| Stereotaxis Inc | 2 | $60 |
| Edwards Lifesciences | 1 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| United Therapeutics Corporation | 2 | $37 |
| AstraZeneca | 3 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Innovation Technologies Inc | 1 | $25 |
| Acist Medical Systems, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$2,713
- EVERA MRI XT DR SURESCAN$1,886
- Micra$1,580
- Carto 3$1,461
- INGEVITY$1,133
- AURORA EV-ICD MRI SURESCAN$962
- AMPLIA MRI QUAD CRT-D SURESCAN$935
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$921
- GENERAL - THERAPIES$882
- US Und$808
- ENSITE$317
- Adapta$313
- Arctic Front$239
- COBALT DR MRI SURESCAN$178
- Definity$120
- AZURE XT DR MRI SURESCAN$110
- NA$109
- EKOSONIC$101
How this compares
$44,576 in reported general payments places this provider in the 75th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
See all clinical cardiac electrophysiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $130,642 |
| XareltoRivaroxaban | 48 | $37,682 |
| EntrestoSacubitril/Valsartan | 14 | $9,978 |
| Flecainide Acetate | 60 | $2,062 |
| Metoprolol Succinate | 80 | $1,222 |
| Amiodarone Hcl | 99 | $1,170 |
| Omeprazole | 36 | $501 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $321 |
| Carvedilol | 29 | $238 |
| SotalolSotalol Hcl | 13 | $221 |
| Rosuvastatin Calcium | 17 | $220 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 53 | $195 |
| ClopidogrelClopidogrel Bisulfate | 16 | $192 |
| Atorvastatin Calcium | 23 | $125 |
| Amlodipine Besylate | 23 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $317 | $130,642134 claims |
| Johnson & JohnsonXarelto | $128 | $37,68248 claims |
| NovartisEntresto | $261 | $9,97814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
Other clinical cardiac electrophysiology in Augusta
- William WhiteAugusta$51K
- Rajan GaneshAugusta$36K
- Haitham HreibeAugusta$34K
- Adam BermanAugusta$16K
- Daniel SohinkiAugusta$14K
- David ClarkAugusta$13K
- David DelurgioAtlanta$695K
- Thomas DeeringAtlanta$237K
- David NewtonSavannah$225K
- Michael LloydAtlanta$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.